Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Contineum Therapeutics (CTNM) EBIT Margin (2023)

Historic EBIT Margin for Contineum Therapeutics (CTNM) over the last 1 years, with Q2 2023 value amounting to 77.87%.

  • Contineum Therapeutics' EBIT Margin changed N/A to 77.87% in Q2 2023 from the same period last year, while for Mar 2024 it was 22.52%, marking a year-over-year change of. This contributed to the annual value of 32.15% for FY2023, which is N/A changed from last year.
  • Contineum Therapeutics' EBIT Margin amounted to 77.87% in Q2 2023.
  • Contineum Therapeutics' EBIT Margin's 5-year high stood at 5559.78% during Q1 2023, with a 5-year trough of 77.87% in Q2 2023.